

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> C08J 3/14, C08G 63/664, 81/00, A61K 9/51, 9/16		<b>A1</b>	<b>(11) International Publication Number:</b> WO 95/03357 <b>(43) International Publication Date:</b> 2 February 1995 (02.02.95)
<b>(21) International Application Number:</b> PCT/US94/08416		<b>(81) Designated States:</b> CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
<b>(22) International Filing Date:</b> 22 July 1994 (22.07.94)		<b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(30) Priority Data:</b> 096,370 23 July 1993 (23.07.93) US 210,677 18 March 1994 (18.03.94) US			
<b>(71) Applicant:</b> MASSACHUSETTS INSTITUTE OF TECHNOLOGY [US/US]; 77 Massachusetts Avenue, Cambridge, MA 02139 (US).			
<b>(72) Inventors:</b> GREF, Ruxandra; 227, rue Jeanne-d'Arc, F-54000 Nancy (FR). MINAMITAKE, Yoshiharu; Apartment #610, 175 Freeman Street, Brookline, MA 02146 (US). LANGER, Robert, S.; 77 Lombard Street, Newton, MA 02158 (US).			
<b>(74) Agent:</b> PABST, Patrea, L.; Kilpatrick & Cody, Suite 1100, 1100 Peachtree Street, Atlanta, GA 30309-4530 (US).			

**(54) Title:** BIODEGRADABLE PARTICLES

**(57) Abstract**

Particles are provided that are not rapidly cleared from the blood stream by the macrophages of the reticuloendothelial system, and that can be modified to achieve variable release rates or to target specific cells or organs. The particles have a biodegradable solid core containing a biologically active material and poly(alkylene glycol) moieties on the surface. The terminal hydroxyl group of the poly(alkylene glycol) can be used to covalently attach onto the surface of the particles biologically active molecules, including antibodies targeted to specific cells or organs, or molecules affecting the charge, lipophilicity or hydrophilicity of the particle. The surface of the particle can also be modified by attaching biodegradable polymers of the same structure as those forming the core of the particles. The typical size of the particles is between 1 nm and 1000 nm, preferably between 1 nm and 100 nm, although microparticles can also be formed as described herein. The particles can include magnetic particles or radiopaque materials, such as air and other gases, for diagnostic imaging, biologically active molecules to be delivered to a site, or compounds for targeting the particles. The particles have a prolonged half-life in the blood compared to particles not containing poly(alkylene glycol) moieties on the surface.

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

1  
BIODEGRADABLE PARTICLES

This invention is in the area of  
biodegradable nanoparticles and microparticles for  
the controlled delivery of biologically active  
5 materials and diagnostic agents.

**Background of the Invention**

A major challenge in the area of the  
parenteral administration of biologically active  
materials is the development of a controlled  
10 delivery device that is small enough for  
intravenous administration and which has a long  
circulating half-life. Biologically active  
materials administered in such a controlled fashion  
into tissue or blood are expected to exhibit  
15 decreased toxic side effects compared to when the  
materials are injected in the form of a solution,  
and may reduce degradation of sensitive compounds  
in the plasma.

A number of injectable drug delivery  
20 systems have been investigated, including  
microcapsules, microparticles, liposomes and  
emulsions. A significant obstacle to the use of  
these injectable drug delivery materials is the  
rapid clearance of the materials from the blood  
25 stream by the macrophages of the  
reticuloendothelial system (RES). For example,  
polystyrene particles as small as sixty nanometers  
in diameter are cleared from the blood within two  
to three minutes. By coating these particles with  
30 block copolymers based on poly(ethylene glycol) and  
poly(propylene glycol), their half-lives were  
significantly increased. L. Illum, S.S. Davis,  
FEBS Lett., 167, 79 (1984). Polystyrene particles,  
however, are not biodegradable and therefore not  
35 therapeutically useful.

Liposomal drug delivery systems have been  
extensively considered for the intravenous

administration of biologically active materials, because they were expected to freely circulate in the blood. It was found, however, that liposomes are quickly cleared from the blood by uptake 5 through the reticuloendothelial system. The coating of liposomes with poly(ethylene glycol) increases their half life substantially. The flexible and relatively hydrophilic PEG chains apparently induce a stearic effect at the surface 10 of the liposome that reduces protein adsorption and thus RES uptake. T.M. Allen, C. Hansen, Biochimica et Biophysica Acta, 1068, 133-141 (1991); T.M. Allen, et al., Biochimica et Biophysica Acta, 1066, 29-36 (1991); V. Torchilin, A. Klibanov, Critical 15 Reviews in Therapeutic Drug Carrier Systems, 7(4), 275-307 (1991); K. Maruyama, et al., Chem. Pharm. Bull., 39(6), 1620-1622 (1991); M.C. Woodle, et al., Biochimica et Biophysica Acta; 193-200 (1992); and D.D. Lasic, et al., Biochimica et Biophysica 20 Acta, 1070, 187-192 (1991); and A. Klibanov, et al., Biochimica et Biophysica Acta, 1062, 142-148 (1991).

European Patent Application Nos. 0 520 888 A1 and 0 520 889 A1 disclose nanoparticles of 25 the block copolymer of polylactic acid and poly(ethylene glycol) for the injectable controlled administration of biologically active materials. The applications do not disclose how to modify the copolymer to vary the profile of drug release nor 30 how modification of the copolymer would affect distribution and clearance of the delivery devices *in vivo*. The applications also do not teach how to prepare nanoparticles that are targeted to specific cells or organs, or how to prepare 35 nanospheres that are useful for gamma-imaging for diagnostic purposes.

U.S. Patent No. 5,145,684 discloses stable, dispersible drug nanoparticles prepared by wet milling in the presence of grinding media in conjunction with a surface modifier.

5 It would be desirable to have particles for the controlled delivery of biologically active materials that are not rapidly cleared from the blood stream by the macrophages of the 10 reticuloendothelial system, that are small enough to be injectable, and that can be modified as necessary to target specific cells or organs or 15 manipulate the rate of delivery of the material.

Therefore, it is an object of the present invention to provide particles for the controlled 15 delivery of biologically active materials that are not rapidly cleared from the blood stream.

It is another object of the present invention to provide particles that can be modified as necessary to target specific cells or organs or 20 manipulate the rate of delivery of the material.

It is another object of the present invention to provide biodegradable particles that contain magnetic materials for diagnostic imaging.

It is still another object of the present 25 invention to provide microparticles for the controlled release of substances or for diagnostic imaging that can optionally be targeted to specific organs or cells.

30

#### **Summary of the Invention**

Particles are provided that are not rapidly cleared from the blood stream by the macrophages of the reticuloendothelial system, and that can be modified as necessary to achieve variable release 35 rates or to target specific cells or organs as desired. The particles have a biodegradable solid core containing a biologically active material

and/or contrast agent for imaging and poly(alkylene glycol) moieties on the surface. The terminal hydroxyl group of the poly(alkylene glycol) can be used to covalently attach onto the surface of the 5 particles biologically active molecules, including antibodies targeted to specific cells or organs, or molecules affecting the charge, lipophilicity or hydrophilicity of the particle. The surface of the particle can also be modified by attaching 10 biodegradable polymers of the same structure as those forming the core of the particles. The typical size of the particles is between 1 nm and 1000 nm, preferably between 1 nm and 100 nm, although microparticles having larger diameters can 15 also be formed as described herein.

The particles can include magnetic particles or radiopaque materials for diagnostic imaging, such as air or other gases, biologically active molecules to be delivered to a site, or 20 compounds for targeting the particles. The particles are useful to administer biologically active materials in a controlled manner intravenously for a wide variety of purposes. The particles can be fabricated in a one-step 25 procedure, and are easily lyophilized and redispersed in aqueous solutions. Biodistribution experiments indicate that the particles have a prolonged half-life in the blood compared to particles not containing poly(alkylene glycol) 30 moieties on the surface.

#### Brief Description of the Figures

Figure 1 is a schematic representation of a cross-section of a nanosphere prepared as described 35 herein that has a biodegradable solid core containing a biologically active material and poly(ethylene glycol) moieties on the surface.

Figure 2 is a gel permeation chromatogram of components in the polymerization reaction of lactide and glycolide in the presence of monomethoxy poly(ethylene glycol) after thirty 5 minutes, one hour, two hours, and four hours. The consumption of lactide and glycolide into the polymer is represented by a decrease in peak D. The shift of peak P over time toward a lower retention time (higher molecular weight) indicates 10 an addition reaction taking place on the hydroxyl end group of the poly(ethylene glycol) chain.

Figure 3 is a thermogram of the exothermic heat flow (expressed in arbitrary units) as a function of temperature, for PEG-PLGA in weight 15 ratios of 1:2, 1:3, 1:4, and 1:9, collected on a Perkin-Elmer Differential Scanning Calorimeter. The sample weight ranged from 20 to 25 mg. Indium was used for temperature and enthalpy calibrations. Each polymer sample was subjected to a heat-cool- 20 heat cycle from -60 to 150°C with a rate of 10°C per minute.

Figure 4 is an X-ray photoelectron spectrum of the surface composition of lyophilized particles of PLGA-PEG using MgK $\alpha$  X-rays at a power of 300W. 25 Figure 5 is a graph of the fraction of poly(ethylene glycol) removed from the surface of the nanospheres during incubation at 37°C in phosphate buffer.

Figure 6 is a graph of the biodistribution 30 of PLGA and PEG-PLGA in the liver and blood as a function of percent of injected dosage over time in minutes (open square, 12 kDa PEG-PLGA in liver; closed diamond, uncoated PLGA in the liver; closed square, 12 kDa PEG-PLGA in blood; and open diamond, 35 uncoated PLGA in the blood).

Figure 7 is a graph of the clearance of PLGA and PEG-PLGA nanospheres in BALB-C mice as a

function of percent of injected dosage in tissue versus time in minutes (open square, PLGA; closed square, PEG 12 kDa; closed triangle, PEG 5 kDa; and open circle, PEG, 20 kDa).

5       Figure 8 is a graph of the accumulation in the liver of PLGA and PEG-PLGA nanospheres in BALB-C mice as a function of percent of injected dosage in tissue versus time in minutes (open square, PLGA; closed square, PEG 12 kDa; closed triangle, PEG 5 kDa; and open circle, PEG, 20 kDa).

10      Detailed Description of the Invention  
Di-block, tri-block and multi-block copolymers are disclosed that contain one or more 15 hydrophobic bioerodible blocks and one or more hydrophilic blocks. Particles formed of these block copolymers are disclosed that are not rapidly cleared from the blood stream by the macrophages of the reticuloendothelial system, and that can be 20 modified as necessary to achieve variable release rates or to target specific cells or organs as desired. The particles can be useful to administer biologically active materials in a controlled manner for a wide variety of purposes.

25

I.      **Copolymers for the Construction of Nanospheres and Microspheres**

30      The period of time of release, and kinetics of release, of the substance from the nanoparticle will vary depending on the copolymer or copolymer mixture or blend selected to fabricate the nanoparticle. Given the disclosure herein, those 35 of ordinary skill in this art will be able to select the appropriate polymer or combination of polymers to achieve a desired effect.

**A. Selection of Polymers****Hydrophilic Polymers**

Poly(alkylene glycol) (which can also be referred to as a poly(alkylene oxide), if the 5 polymer was prepared from an oxide instead of a glycol) is employed as the terminal hydrophilic block or blocks of the block copolymer. As used herein, the term poly(alkylene glycol) refers to a polymer of the formula  $\text{HO-}[(\text{alkyl})\text{O}]_y\text{-OH}$ , wherein 10 alkyl refers to a  $\text{C}_1$  to  $\text{C}_4$  straight or branched chain alkyl moiety, including but not limited to methyl, ethyl, propyl, isopropyl, butyl, and isobutyl. Y is an integer greater than 4, and typically between 8 and 500, and more preferably 15 between 40 and 500.

*In vivo* results show that the higher the molecular weight (MW) of PEG, the longer the circulation time in the blood (the half-life). (See Figures 7 and 8).

20 Specific examples of poly(alkylene glycol) include poly(ethylene glycol), polypropylene 1,2-glycol poly(propylene oxide), and polypropylene 1,3-glycol. A preferred hydrophilic polymeric moiety is PEG of a molecular weight of 25 approximately 20,000 Da. Other hydrophilic polymers that can be used in place of poly(alkylene glycol) are polypyrrolidone, dextrans, and poly(vinyl alcohol) with a different percent acetyl content. A suitable commercial product is 30 Pluronic<sup>TM</sup> F68 (BASF Corporation), a copolymer of polyoxyethylene and polyoxypropylene, which is approved by the U.S. Food and Drug Administration (FDA).

35

**Hydrophobic Bioerodible Polymers**

A polymer should be selected for the internal hydrophobic block or blocks of the

copolymer that is biodegradable, biocompatible, and that has a terminal group that can react with the terminal hydroxyl group of the poly(alkylene glycol) to form a covalent linkage. It has been 5 reported that the block copolymer of polylactic acid and poly(ethylene glycol) can be used for the injectable controlled administration of biologically active materials. However, it has now 10 been discovered that the copolymer of lactic acid and glycolic acid, as well as other polymers such as polyanhydrides, polyorthoesters, polyphosphazenes, polyphosphates, polyhydroxy acids other than the homopolymer of lactic acid, and 15 specifically including polyhydroxybutyric acid, polycaprolactone, or copolymers prepared from the monomers of these polymers can also be used to prepare nanoparticles for the delivery of biologically active materials. The variety of 20 materials that can be used to prepare the particles significantly increases the diversity of release rate and profile of release that can be accomplished *in vivo*.

Biodegradable hydrophobic polyanhydrides are disclosed in, for example, U.S. Patent Nos. 25 4,757,128, 4,857,311, 4,888,176, and 4,789,724. Polyhydroxybutyrate is disclosed in Agostini, S., "Synthesis and Characterization of PHB," Ph.D. thesis, Case Western University, U.S.A. (1971) and U.S. Patent No. 3,044,942. The teachings of these 30 publications is incorporated by reference herein.

In a preferred embodiment, polyesters of poly(lactic-co-glycolic) acid (PLGA) form the core of the particles. These polymers are approved for parenteral administration by the FDA. Because PLGA 35 degrades via hydrolysis, *in vivo* degradation rates can be predicted from *in vitro* data. PLGA degrades to lactic and glycolic acids, substances found

naturally in the body. Furthermore, by manipulating the molar ratio of lactic and glycolic acid and the molecular weight of the copolymers, different degradation patterns can be obtained.

5 The molecular weight of the polymer used to fabricate the nanoparticle and the chemical composition and stereochemical configuration of the polymer will affect the solubility of the polymer in various organic solvents as well as the  
10 crystallinity of the polymer. In this regard, a copolymer between lactic acid and glycolic acid is preferable.

To be ensure elimination from the body, the PEG should have a molecular weight of between  
15 approximately 300 and 20,000 Daltons. Several diblock copolymers of PEG-PLGA have been evaluated in which the molecular weight of PEG ranged from 350 to 20,000 Da, and the molecular weight of PLGA ranged from 350 to 200,000 Da. It was determined  
20 that the molecular weight of the hydrophilic and hydrophobic regions of the particle affect the water solubility of the particles and thus their stability in aqueous solutions. As an example, PEG:PLGA 1:1 (weight ratio), (molecular weight PEG  
25 = molecular weight PLGA = 5,000 Daltons) is freely soluble in water and can be used to form micelles of a mean diameter of about 20 nm as determined by using QELS (quasi elastic light scattering). To form larger nanoparticles with a dense core, this  
30 polymer should be blended with a hydrophobic polymer, such as PLGA.

The solubility in water or phosphate buffer solution (pH 7.4) decreases as the MW of PLGA increases from 5,000 to 20,000 Da. With PLGA-PEG  
35 (20,000-5,000 Da) stable nanospheres of a mean diameter of 120 to 140 nm were obtained using a simple emulsion technique. PLGA copolymers are

preferred as the second polymer in the particle because it is soluble in ethyl acetate and acetone. Ethyl acetate or acetone is preferred over dichloromethane and chloroform because they are 5 less toxic for *in vivo* applications.

Poly L-lactide is a polymer with a high degree of crystallinity. Poly D,L-lactide is less crystalline and more soluble in organic solvents. A random copolymer of D,L-lactide and glycolide in 10 the ratio of 75:25 is very soluble in organic solvents, in particular, ethyl acetate. This copolymer is completely amorphous, which renders it a useful polymer for the fabrication of nanospheres and microspheres for controlled release.

15 Poly-L-lactide has a degradation time *in vitro* of months to years. The long degradation time is due to its higher crystallinity which protects the polymer from water penetration. Since D,L-lactide is amorphous, its degradation time is 20 typically one to a number of months. Poly-glycolide also has a crystalline structure and a degradation time of one to several months. D,L-PLGA is amorphous, with a degradation time *in vitro* of weeks to months. As the glycolic acid ratio is 25 increased, the rate of degradation is enhanced. Lactic acid has bulky methyl groups on the alpha carbon (-O-CH(CH<sub>3</sub>-CH-) which makes it difficult for water molecules to access, while glycolic acid has a proton on the alpha carbon (-O-CH<sub>2</sub>-CO-), which 30 allows easier access of water molecules to the ester bonds.

#### B. Preparation of diblock copolymers.

The preparation of the diblock copolymer of any of these hydrophobic polymers with 35 poly(alkylene glycol) (PAG), and preferably poly(ethylene glycol), can be accomplished in a number of ways. Methods include: (i) reacting the

polymer with monomethoxy poly(alkylene glycol), such as monomethoxy PEG or PEG protected with another oxygen protecting group known to those of skill in the art (such that one terminal hydroxyl group is protected and the other is free to react with the polymer); or (ii) polymerizing the polymer onto monomethoxy or otherwise monoprotected PAG, such as monoprotected PEG. Several publications teach how to carry out the latter type of reaction.

10 Multiblock polymers have been prepared by bulk copolymerization of D,L-lactide and PEG at 170-200°C (X.M. Deng, et al., J. of Polymer Science: Part C: Polymer Letters, 28, 411-416 (1990). Three and four arm star PEG-PLA copolymers have been made

15 by polymerization of lactide onto star PEG at 160°C in the presence of stannous octoate as initiator. K.J. Zhu, et al., J. Polym. Sci., Polym. Lett. Ed., 24, 331 (1986). Triblock copolymers of PLA-PEG-PLA have been synthesized by ring opening

20 polymerization at 180-190°C from D,L-lactide in the presence of PEG containing two end hydroxyl groups using stannous octoate as catalyst, without the use of solvent. The polydispersity (ratio Mw to Mn) was in the range of 2 to 3.

25 In an alternative embodiment, the polymer or monomers can be reacted with a poly(alkylene glycol) that is terminated with an amino function (available from Shearwater Polymers, Inc.) to form an amide linkage, which is in general stronger than an ester linkage. The amide linkage may provide a longer period of retention of the poly(alkylene glycol) on the surface of the nanoparticle.

30 Triblock or other types of block copolymers terminated with poly(alkylene glycol), and in particular, poly(ethylene glycol), can be prepared using the reactions described above, using a branched or other suitable poly(alkylene glycol)

and protecting the terminal groups that are not to be reacted. Shearwater Polymers, Inc., provides a wide variety of poly(alkylene glycol) derivatives. Examples are the triblock PEG-PLGA-PEG and the 5 polymer of the structure



10 Linear triblock copolymers such as PEG-PLGA-PEG can be prepared by refluxing the lactide, glycolide and polyethyleneglycol in toluene in the presence of stannous octoate. The triblock copolymer can also be prepared by reacting  $\text{CH}_3-\text{O}(\text{CH}_2\text{CH}_2)_n-\text{O-PLGA-OH}$  with HO-PLGA.

15 In one embodiment, a multiblock copolymer is prepared by reacting the terminal group of the hydrophobic polymeric moiety such as PLA or PLGA with a suitable polycarboxylic acid monomer, 20 including but not limited to 1,3,5-benzenetricarboxylic acid, butane-1,1,4-tricarboxylic acid, tricarballylic acid (propane-1,2,3-tricarboxylic acid), and butane-1,2,3,4-tetracarboxylic acid, wherein the carboxylic acid 25 moieties not intended for reaction are protected by means known to those skilled in the art. The protecting groups are then removed, and the remaining carboxylic acid groups reacted with poly(alkylene glycol). In another alternative 30 embodiment, a di, tri, or polyamine is similarly used as the branching agent.

**II. Incorporation of Biologically Active Material or Diagnostic Agent within or onto Particles**

35 There are basically two different embodiments of the particles wherein biologically active and/or diagnostic agents are incorporated with the particles. In the first embodiment, the biologically active agent or diagnostic agent is

encapsulated within the particle for delivery and/or release of the agent. In the second embodiment, the agent is coupled to the block copolymers, either for enhanced stability of 5 incorporation into the particle or for targeted delivery of the particles. Particles can include elements of both embodiments. For example, a particle can be prepared that includes a substance to be delivered and a polymer that is covalently 10 bound to a biologically active molecule, such as an antibody or antibody fragment, wherein the particle is prepared in such a manner that the biologically active molecule is on the outside surface of the particle. Particles with antibody or antibody 15 fragments on their surfaces can be used to target specific cells or organs as desired for the selective dosing of drugs. Other targeting ligands include ligands to tissue specific receptors, hormones, and lectins.

20 The particles prepared as described herein can be used for cell separation, as well as targeted to specific tissues, by attaching to the surface of the particle specific ligands for given cells in a mixture of cells. When magnetic 25 particles are also incorporated, the particles can be targeted using the ligands, such as tissue specific receptors or antibodies to tissue specific surface proteins, then maintained at the targeted cells using a magnetic field while the particles 30 are imaged or a compound to be delivered is released. For example, in one embodiment, carmustine (BCNU) or other anti-cancer agent such as cis-platin is incorporated in the core of the particles and antibodies to the target cancerous 35 cells are covalently bound to the surface of the particle.

**Coupling of Agents to Polymer**

The biologically active molecule, and in particular, a protein such as an antibody or antibody fragment, can be covalently bound to the 5 block copolymer by reaction with the terminal hydroxyl group of the poly(alkylene glycol) by any method known to those skilled in the art. For example, the hydroxyl group can be reacted with a terminal carboxyl group or terminal amino group on 10 the molecule or antibody or antibody fragment, to form an ester or amide linkage, respectively. Alternatively, the molecule can be linked to the poly(alkylene glycol) through a difunctional spacing group such as a diamine or a dicarboxylic 15 acid, including, but not limited to, sebacic acid, adipic acid, isophthalic acid, terephthalic acid, fumaric acid, dodecanedicarboxylic acid, azeleic acid, pimelic acid, suberic acid (octanedioic acid), itaconic acid, biphenyl-4,4'-dicarboxylic 20 acid, benzophenone-4,4'-dicarboxylic acid, and p-carboxyphenoxyalkanoic acid. In this embodiment, the spacing group is reacted with the hydroxyl group on the poly(alkylene glycol), and then reacted with the biologically active molecule. 25 Alternatively, the spacing group can be reacted with the biologically active molecule or antibody or antibody fragment, and then reacted with the hydroxyl group on the poly(alkylene glycol).

The reaction should be accomplished under 30 conditions that will not adversely affect the biological activity of the molecule being covalently attached to the nanoparticle. For example, conditions should be avoided that cause the denaturation of proteins or peptides, such as 35 high temperature, certain organic solvents and high ionic strength solutions, when binding a protein to the particle. For example, organic solvents can be

eliminated from the reaction system and a water-soluble coupling reagent such as EDC used instead.

In a preferred embodiment, the particle includes a substance to be delivered and a 5 copolymer of poly(alkylene glycol) with poly(lactic-co-glycolic acid), poly(lactic-acid), poly(glycolic acid), or polyanhydride, wherein the poly(alkylene glycol) is covalently bound to an antibody or antibody fragment. The particles can 10 be used to release over long periods of time highly active and effective drugs, such as anticancer drugs, that produce significant side effects when administered systemically. The controlled release generally decreases the toxic side effects 15 associated with systemic administration of the non-encapsulated drug. The polymeric matrix can also provide protection of the drugs against degradation in the plasma for drugs with short biological half-lives.

20 **Incorporation of Substances within the Particles for Delivery or Diagnostic Purposes.**

A wide range of biologically active materials or drugs can be incorporated into the polymer at the time of particle formation. The 25 substances to be incorporated should not chemically interact with the polymer during fabrication, or during the release process. Additives such as inorganic salts, BSA (bovine serum albumin), and inert organic compounds can be used to alter the 30 profile of substance release, as known to those skilled in the art. Biologically-labile materials, for example, prokaryotic or eukaryotic cells, such as bacteria, yeast, or mammalian cells, including human cells, or components thereof, such as cell 35 walls, or conjugates of cellular can also be included in the particle. The term biologically active material refers to a peptide, protein, carbohydrate, nucleic acid, lipid, polysaccharide

or combinations thereof, or synthetic inorganic or organic molecule, that causes a biological effect when administered *in vivo* to an animal, including birds and mammals, especially humans.

5 Nonlimiting examples are antigens, enzymes, hormones, receptors, and peptides. Examples of other molecules that can be incorporated include nucleosides, nucleotides, antisense, vitamins, minerals, and steroids. Specific biologically 10 active agents include anti-inflammatory compounds, anesthetics, chemotherapeutic agents, immunotoxins, immunosuppressive agents, steroids, antibiotics, antivirals, antifungals, and anticoagulants.

Hydrophobic drugs such as lidocaine or 15 tetracaine can be entrapped into the particles and are released over several hours. Loadings in the nanoparticles as high as 40% (by weight) have been achieved. Hydrophobic materials are more difficult to encapsulate, however, and in general, the 20 loading efficiency is decreased over that of a hydrophilic material.

In one embodiment, an antigen is incorporated into the nanoparticle. The term antigen includes any chemical structure that 25 stimulates the formation of antibody or elicits a cell-mediated humoral response, including but not limited to protein, polysaccharide, nucleoprotein, lipoprotein, synthetic polypeptide, or a small molecule (hapten) linked to a protein carrier. The 30 antigen can be administered together with an adjuvant as desired. Examples of suitable adjuvants include synthetic glycopeptide, muramyl dipeptide. Other adjuvants include killed *Bordetella pertussis*, the liposaccharide of Gram-negative bacteria, and large polymeric anions such 35 as dextran sulfate. A polymer, such as a polyelectrolyte, can also be selected for

fabrication of the nanoparticle that provides adjuvant activity. Specific antigens that can be loaded into the nanoparticles described herein include, but are not limited to, attenuated or 5 killed viruses, toxoids, polysaccharides, cell wall and surface or coat proteins of viruses and bacteria. Examples of organisms from which these antigens are derived include poliovirus, rotavirus, hepatitis A, B, and C, influenza, rabies, HIV, 10 measles, mumps, rubella, *Bordetella pertussus*, *Streptococcus pneumoniae*, *C. diphteria*, *C. tetani*, *Cholera*, *Salmonella*, *Neisseria*, and *Shigella*.

Materials can also be incorporated into the particles for diagnostic purposes. Examples 15 include radiolabels, radiopaque materials such as air or barium, fluorescent compounds, and magnetic materials. For example, hydrophobic fluorescent compounds such as rhodamine can be incorporated into the core of the particles. Hydrophilic 20 fluorescent compounds can also be incorporated, however, the efficiency of encapsulation is smaller, because of the decreased compatibility of the hydrophobic core with the hydrophilic material. The hydrophilic material must be dissolved 25 separately in water and a multiple emulsion technique used for fabrication of the particle.

Contrast agents that can be incorporated include gases, which are particular useful in 30 ultrasound imaging. Appropriate gases can be incorporated into the polymeric materials at the time of hydrogel formation, for example, air, argon, nitrogen, carbon dioxide, nitrogen dioxide, methane, helium, neon, oxygen and perfluorocarbon. Sterilized air or oxygen is a preferred imaging 35 contrast agent for *in vivo* applications.

Another preferred example is a gamma-labelled nanoparticle that can be used to monitor

the biodistribution of the particle *in vivo*. Any pharmaceutically acceptable gamma-emitting moiety can be used, including, but not limited to, indium and technetium. The magnetic particles can be 5 prepared as described herein, or alternatively, magnetic nanoparticles, including surface-modified magnetic nanoparticles can be purchased commercially, the surface further modified by attaching the hydrophilic polymeric coating. For 10 example, the magnetic nanoparticle can be mixed with a solution of the hydrophilic polymer in a manner that allows the covalent binding of the hydrophilic polymer to the nanoparticle. Alternatively, a gamma-emitting magnetic moiety is 15 covalently attached to the hydrophilic or hydrophobic polymeric material of the particle. The larger the size of the magnetic moiety, the larger the size of the resulting particles obtained using PLGA-PEG, or blends of PLGA-PEG with another 20 polymer.

Examples of suitable materials for MRI include the gatalinium chelates currently available, such as diethylene triamine pentaacetic acid (DTPA) and Gatripentotate dimeglumine, as well 25 as iron, magnesium, manganese, copper and chromium. These are typically administered in a dosage equivalent to 14 ml for a 70 kg person of a 0.5 M/liter solution.

Examples of materials useful for CT and 30 x-rays include iodine based materials for intravenous administration such as ionic monomers typified by Diatrizoate and iothalamate (administered at a dosage of 2.2 ml of a 30 mg/ml solution), non-ionic monomers typified by 35 iopamidol, isohexol, and ioversol (administered at a dosage of 2.2 ml of a 150 to 300 mg/ml solution), non-ionic dimers typified by iotrol and iodixanol,

and ionic dimers, for example, ioxagalte. Other useful materials include barium for oral use.

### III. Preparation and Characterization of Nanoparticles

#### 5 Size of Particles

As described herein, the typical size of the particles which can be produced is between 80 nm and 10,000 nm, most preferably between 80 nm and 700 nm. Although the examples describe production 10 of nanoparticles, it is possible to increase the diameter of the resulting particles to form microparticles having a diameter of one micron or greater. For ease of reference herein in the general descriptions, both microparticles and 15 nanoparticles will be referred to as particles unless otherwise specified.

As used herein, the term nanoparticle refers to a solid particle of size ranging from 10 to 1000 nm. A particularly preferred nanoparticle 20 is biodegradable, biocompatible, has a size of less than 200 nm and has a rigid biodegradable core that has incorporated in it the substance to be delivered.

The term "microparticle," as used herein, 25 refers to a particle of size ranging from greater than one micron to 1000 microns. Any of the nanoparticles described herein can be alternatively fabricated as microparticles if more appropriate for the desired application.

#### 30 Structure of Particles.

Figure 1 is a schematic representation of a cross-section of a particle prepared as described herein. As illustrated, the particle has a biodegradable solid core containing a biologically 35 active material and poly(alkylene glycol) moieties on the surface. The surface poly(alkylene glycol) moieties have a high affinity for water that reduces protein adsorption onto the surface of the

particle. The recognition and uptake of the particle by the reticulo-endothelial system (RES) is therefore reduced. The terminal hydroxyl group of the poly(alkylene glycol) can be used to 5 covalently attach biologically active molecules, or molecules affecting the charge, lipophilicity or hydrophilicity of the particle, onto the surface of the particle.

A nanosphere refers to a nanoparticle that 10 is spherical in shape. The shape of the nanoparticles prepared according to the procedures herein or otherwise known is easily determined by scanning electron microscopy. Spherically shaped nanoparticles are preferred for circulation through 15 the bloodstream. If desired, the particles can be fabricated using known techniques into other shapes that are more useful for a specific application.

#### **Degradation Properties.**

The term biodegradable or bioerodible, as 20 used herein, refers to a polymer that dissolves or degrades within a period that is acceptable in the desired application (usually *in vivo* therapy), usually less than five years, and preferably less than one year, on exposure to a physiological 25 solution of pH 6-8 having a temperature of between 25 and 37°C. In a preferred embodiment, the nanoparticle degrades in a period of between 1 hour and several weeks, according to the application.

#### **Composition of Particles**

30 There are a number of specific embodiments of the particles described herein. In a first embodiment, a particle is provided that is prepared from a diblock, triblock, or multiblock copolymer of poly(alkylene glycol) with poly(lactic-co-glycolic acid). In a second embodiment, an 35 particle is provided that is prepared from a copolymer of poly(alkylene glycol) with a

polyanhydrides, polyphosphates, polyphosphazenes, polyorthoesters, polyhydroxy acids other than the homopolymer of lactic acid, and specifically including polyhydroxybutyric acid,

5      polycaprolactone, or copolymers prepared from the monomers of these polymers, wherein the copolymer can be of diblock, triblock, or multiblock structure. For examples, the particle can be made from a copolymer of the form poly(alkylene glycol)-

10     [poly(lactic-co-glycolic acid) or poly(lactic acid)]-poly(alkylene glycol). In yet another embodiment, the particle can be made from a copolymer of a poly(lactic acid) or poly(glycolic acid), with two or more moieties of poly(alkylene glycol). Alternatively, the particle can be made

15     from a copolymer of a poly(lactic-co-glycolic acid), poly(lactic acid), or poly(glycolic acid) with poly(alkylene glycol), wherein the copolymer is blended with poly(lactic-co-glycolic acid).

20      **Preparation of Particles**

Particles are prepared by dissolving a block copolymer in a first solvent and then precipitating the block copolymer from a solvent system in such a manner that the hydrophobic moieties of the copolymer are in the core of the particle and the hydrophilic poly(alkylene glycol) moieties are on the surface of the particle. Optionally, a substance to be delivered can be simultaneously encapsulated in the resulting particle encapsulates the substance. The substance to be delivered is mixed with the copolymer or copolymer blend in a ratio of greater than 0 to 99, and more preferably, in a ratio of 1 to 70, prior to forming the particles.

35      For example, a solution of block copolymer in a suitable solvent, such as ethyl acetate or methylene chloride, is prepared. An organic

solvent should be selected that is a nonsolvent for the poly(alkylene glycol) homopolymer, and a solvent for the homopolymer of the other unit or units of the block copolymer. An emulsion is 5 formed by adding distilled deionized water to the solution. Slow evaporation of the organic solvent allows a reorganization of the polymer chains inside and on the surface of the droplets. The poly(alkylene glycol), which is not soluble in 10 organic solvent, tends to migrate to the aqueous phase, while the other unit of the copolymer, which is not soluble in water, remains inside the droplets and forms the core of the particles after all of the solvent is evaporated. PEG chains 15 inside the core should be avoided, because this can lead to absorption of water by the core followed by the accelerated and uncontrolled release of an encapsulated substance.

After removing the organic solvent, the 20 particles are isolated from the aqueous phase by centrifugation. They can later be readily redispersed in water.

In an alternative embodiment, acetone, methanol, or ethanol and their aqueous solutions 25 can be used in place of the distilled deionized water. In general, water is preferred because it forces a higher concentration of poly(alkylene glycol) to the surface of the particle. However, acetone can be used as the precipitating solvent of 30 the copolymer or second polymer, such as polyanhydride, is sensitive to water.

In an alternative embodiment, the block copolymer is blended with a second polymer, for example PLGA-PEG mixed with PLGA or PLA, prior to 35 fabrication into the particles, to provide different properties on the particles, for example,

altering their half-life *in vivo*. Addition of PLGA PEG to other polymers increases *in vivo* half-life.

In a typical embodiment, the second polymer is mixed with the block copolymer in a ratio of 5 greater than 0 up to 100.

Light scattering studies have indicated that the size of the resulting particles is determined by the viscosity of the organic phase, ratio of organic to aqueous phase, and sonication 10 power and time: increased viscosity yields bigger particles and higher ratio of aqueous phase volume as compared to organic phases yields smaller particles. A example of the effect of the sonication power and time is as follows: 25 mg 15 polymer/2 ml CH<sub>2</sub>Cl<sub>2</sub> is added to 30 ml of 0.3% polyvinyl alcohol solution. The mixture is vortexed for 30 seconds at the maximum strength and then sonicated by probe sonicator for 30 seconds at the output 7. The conditions reproducibly yield 15 20 nm particles. These parameters can be optimized to obtain nanospheres of a mean size of about 150 nm with a narrow unimodal size distribution.

#### **Modification of Surface Properties of Particles**

25 In another embodiment, the poly(alkylene glycol) can be bound to a compound that affects the charge, lipophilicity or hydrophilicity of the particle. For example, a polymer other than poly(alkylene glycol) is used as the surface 30 hydrophilic coating. Any biocompatible hydrophilic polymer can be used for this purpose, including, but not limited to, poly(vinyl alcohol). The particle can also be coated with a dextran, which are in general more hydrophilic than poly(alkylene 35 glycol) but less flexible. Dextran coated nanoparticles are particularly useful for magnetic resonance imaging (MRI).

**Preparation of Particles from Polymers  
Covalently Bound to a Biologically Active  
Molecule**

In yet another embodiment, particles are  
5 made from a block copolymer that is covalently  
bound to a biologically active molecule, for  
example, an antibody or antibody fragment, such as  
the Fab or Fab<sub>2</sub> antibody fragments, or to a  
targeting molecule, wherein the particle is  
10 prepared in such a manner that the biologically  
active molecule is on the outside surface of the  
particle. The biologically active molecule can be  
a protein, carbohydrate or polysaccharide, nucleic  
acid, lipid, a combination thereof, or a synthetic  
15 molecule, including organic and inorganic  
materials, as described above.

**IV. Detection of Particles including Detectable  
Agents**

Due to their *in vivo* stability, the  
20 particles are useful for vascular imaging in liver  
and renal diseases, fallopian tube diseases,  
detecting and characterizing tumor masses and  
tissues, and measuring peripheral blood velocity,  
as well as the more standard applications.

25 The method for imaging by detection of gas  
bubbles in the particles in a patient uses a  
transducer which produces pulses, illustrative of  
ultrasonic acoustic energy, having predetermined  
frequency characteristics. A first pulse has an  
30 increasing frequency with time, and a second pulse  
has a decreasing frequency with time. Imaging  
arrangements produce images of the region within  
the specimen after exposure to the first and second  
pulses.

35 The conventional technique for determining  
the presence of bubbles in the blood stream uses a  
Doppler shift in the frequency of the ultrasonic  
acoustic energy which is reflected by the blood.

The amplitude of the Doppler bubble signal increases nearly proportionally with increases in the radius of the bubble. The human hearing mechanism is considered the most accurate processor 5 for recognizing whether bubble signals are present or absent. For this reason, it is preferable to have a skilled operator to obtain satisfactory results using Doppler blood flow monitoring equipment.

10 To determine whether the air-filled particles are useful for *in vivo* imaging, the following *in vitro* method can be used.

Particles prepared by the above methods are suspended in a capped tissue culture tube. For 15 ultrasound imaging, the tubes are placed on top of a pad covered with coupling medium above the transducer. The transducer is held in place at roughly a 90° angle of incidence to minimize any motion artifacts. The transducer acts as a 20 transmitter and also receives ultrasound radiation scattered back from the tube. B-mode and Doppler images are established for tubes filled with polymeric microcapsules and the resulting images are compared with a control consisting of an image 25 from a tube containing buffer alone. The B-mode of display gives a two dimensional image of a slice through the scanned tube. The results correlate well with the *in vivo* results, as shown by Doppler imaging techniques (described below). Since the *in* 30 *vitro* and *in vivo* data showed a high degree of correlation in the working examples, this test is reasonably predictive of the *in vivo* stability of microparticles.

Other means of detection include PET 35 (positron emission tomograph), (CAT) computer assisted tomography, x-rays, fluoroscopy, and MRI (magnetic resonance imaging). These are conducted

using the standard techniques and equipment as used with other commercially available contrast agents.

The same particles useful in imaging using the more common techniques such as ultrasound, 5 magnetic resonance imaging (MRI), computer tomography (CT), x-ray, are useful in the less common positron emission tomography (PET) and single photon emission computerized tomography (PET).

10 Nanospheres prepared as described herein can be labelled with Indium 111, which has been used for gamma-scintigraphy studies in humans. Its short half-life (six hours) reduces the problems of disposal and contamination. Indium 111 also has 15 lower energy radiation compared to other labels. These properties render it an attractive compound for labelling nanospheres for *in vivo* studies.

The radioactive label can be attached to the surface of the already prepared nanospheres by 20 first chelating In and diethyltriaminopentaacetic acid (DTPA) by mixing both compounds in aqueous ethanol, then reacting primary amino groups in this chelate with carboxy groups on the particles' surface (ester group in PLGA on the surface should 25 partially hydrolyzed to produce free carboxylic acids) by EDC to provide surface-labeled particles. Alternatively, the label is incorporated into the core during fabrication. The release of the label should be slow enough that sufficient radioactivity 30 will be retained in the device for evaluation of the *in vivo* organ distribution by gamma-scintigraphy.

**V. Pharmaceutical Administration of Particles**

The particles described herein can be 35 administered to a patient in a variety of routes, for example, orally, parenterally, intravenously,

intradermally, subcutaneously, or topically, in liquid, cream, gel or solid form.

The particles can be lyophilized and then formulated into an aqueous suspension in a range of 5 microgram/ml to 100 mg/ml prior to use.

Alternatively, the particles can be formulated into a paste, ointment, cream, or gel, or transdermal patch.

For drug delivery, the particles should 10 contain the substance to be delivered in an amount sufficient to deliver to a patient a therapeutically effective amount of compound, without causing serious toxic effects in the patient treated. The desired concentration of 15 active compound in the particle will depend on absorption, inactivation, and excretion rates of the drug as well as the delivery rate of the compound from the particle. It is to be noted that dosage values will also vary with the severity of 20 the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering 25 or supervising the administration of the compositions.

The particles can be administered once, or 30 may be divided into a number of smaller doses to be administered at varying intervals of time, depending on the release rate of the particle, and the desired dosage.

Controlled delivery devices prepared as described herein can also be used as ocular inserts for extended release of drugs to the eye.

35 **VI. Coatings of Implantable Devices**

Polymers prepared as described herein can also be used to coat implantable devices, such as

stents, catheters, artificial vascular grafts, and pacemakers. The device can be coated with the lyophilized powder of the particles, or otherwise as known to those skilled in the art. The coating 5 can also be used to release antibiotics, anti-inflammatories, or anti-clotting agents at a predetermined rate, to prevent complications related to the implanted devices.

10                   **Non-Pharmaceutical Uses for the Particles**  
Non-pharmaceutical uses for the particles include delivery of food additives, including stabilizers and dispersants or other viscosity modifying agents, controlled and selective delivery 15 of pesticides, herbicides, insecticides, fertilizer, and pheromones, and in color and ink formulations in the printing and ink industry.

Examples

20                   The following examples below disclose the preparation of specific di- tri- and multiblock copolymers of hydrophobic biodegradable polymers such as PLA and PLGA, and hydrophilic poly(alkylene glycols) (PAG) such as PEG, the covalent attachment 25 of an antibody to the polymers, the formation of nanospheres from the polymers, the incorporation of a biological substance into the nanospheres, and the biodistribution of the particles *in vivo*.

Given this detailed description, one of 30 skill in the art will know how to produce a wide variety of multiblock copolymers suitable for fabrication into nanospheres, how to covalently link antibodies and antibody fragments to the copolymers, how to prepare nanospheres from the 35 particles and how to incorporate biological material and diagnostic agents into nanospheres.

Materials and Methods.

Low toxicity stannous octoate was purchased from ICN. D,L-lactide was purchased from Aldrich Chemical Company, and glycolide from Polysciences, Inc. These compounds were recrystallized before use from ethyl acetate. High purity monomethoxy PEG (M-PEG) with molecular weight 5,000, 12,000 and 20,000 was purchased from Shearwater Polymers, Inc. The number average molecular weight of the polymer was determined with on a Perkin-Elmer GPC system with an LC-25 refractive index detector equipped with a mixed bed Phenogel column filled with 5  $\mu$ m particles from Phenomenex. Chloroform was used as the eluent, with a flow rate of 0.9 ml/min. The molecular weights were determined relative to narrow molecular weight polystyrene and poly(ethylene glycol) standards from Polysciences.

Thermal transition data was collected with a Perkin-Elmer DSC-7 (Newton Center, MA). The sample weight ranged from 20 to 25 mg. Indium was used for temperature and enthalpy calibrations. Each sample was subjected to a heat-cool-heat cycle from -60 to 150°C with a rate of 10°C/min. Wide angle x-ray diffraction spectra were obtained with a Rigaku Rotaflex Diffractometer from Rigaku Corporation (Danvers, MA) with S=0.05 using a Nickel filtered Cu K $\alpha$  source. The data was analyzed on a Micro Vax II computer. The IR spectra were recorded on a Nicolet 500 spectrometer using a polymer powder melted on sodium chloride crystals to obtain thin films.  $^{13}\text{C}$  NMR studies were conducted on samples dissolved in deuterated chloroform with a Nicolet NT-360 spectrometer. Peak fitting was carried out with a VG data system.

**Example 1: Preparation of PLGA-PEG by Linking PLGA and PEG.**

The diblock copolymer PLGA-PEG was formed by reacting the hydroxyl endgroup of monomethoxy-PEG (M-PEG) with the carboxylic endgroup of PLGA. PLGA (0.1 mmol) and M-PEG (1.2 mmol) were dissolved in a mixture 5:2 of methylene chloride and dimethyl formamide. Equivalents of 1.2 mmol of 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide (EDC) and DMAP were added. After 24 hours of reaction at room temperature, the polymer was precipitated with water to remove non-reacted PEG and coupling reagents. The solid product was collected by centrifugation and washed three times with water. As detected by GPC, approximately 10% of diblock copolymer was formed.

**Example 2: Preparation of PLGA-PEG by Polymerization of Lactic Acid and Glycolic Acid onto PEG.**

European Patent Application Nos. 0 520 888 A1 and 0 520 889 A1A disclose that PLA-PEG diblock copolymer can be prepared from PEG lactic acid at 114°C using toluene as the solvent and stannous octoate as the catalyst. This method was employed to synthesize a series of diblock copolymers of PLGA-PEG, starting with PEG of various chain lengths and progressively increasing the chain length of PLGA by decreasing the initial amount of PEG in the reaction mixture.

All siliconized glassware was heated at 130°C overnight and cooled under vacuum before use. Lactide (4 g) and glycolide (1 g) were recrystallized from dry ethyl acetate the day before the polymerization reaction and dried under vacuum overnight. The monomers were added to the polymerization flasks and allowed to dissolve in dry toluene (10 ml) under argon, together with

various amounts of PEG (0.5 to 5 g). The mixture was heated to 114°C and then stannous octoate (10 mg) dissolved in toluene was added to the mixture.

Samples were collected periodically and 5 analyzed with GPC to determine the advancement of the reaction. Figure 2 is a gel permeation chromatogram of components in the polymerization reaction of lactide and glycolide in the presence of monomethoxy poly(ethylene glycol) after thirty 10 minutes, one hour, two hours, and four hours. The consumption of lactide and glycolide into the polymer is represented by a decrease in peak D. The shift of peak P over time toward a lower 15 retention time (higher molecular weight) indicates an addition reaction occurring on the hydroxyl end group of the poly(ethylene glycol) chain.

It was determined that the higher the ratio of PEG in the reaction solution, the faster the reaction. For example, when PEG (MW 5000) is 20 reacted with lactide and glycolide in a weight ratio of 50:50 PEG to monomers, the reaction is complete in less than twenty minutes. When PEG (MW 5000) is reacted with lactide and glycolide in a weight ratio of 10:90 PEG to monomers, the reaction 25 is complete in approximately five hours.

After the starting materials were consumed, the reaction was stopped by cooling the reaction mixture to 0°C and removing the toluene. The polymer product was redissolved in methylene 30 chloride and purified by precipitation with hexane. After three reprecipitations, the polymer was washed with water.

Figure 3 is a graph of the change in temperature (°C) for PEG-PLGA in weight ratios of 35 1:2, 1:3, 1:4, and 1:9, collected on a Perkin-Elmer Differential Scanning Calorimeter. The sample weight ranged from 20 to 25 mg. Indium was used

for temperature and enthalpy calibrations. Each cycle was subjected to a heat-cool-heat cycle from -60 to 150°C with a rate of 10°C per minute.

5 Random lactic acid-ethylene oxide copolymers show two distinct Tg's, suggesting a phase separation inside the polymer. The single Tg observed in this case may be due to an entanglement effect of long PEG and PLGA chains in the polymers, which cannot easily phase-separate.

10 Polymer characterization nuclear magnetic resonance confirmed that the product was pure diblock PEG-PLGA. The polymers were used to form the nanospheres for parenteral administration.

15 **Example 3: Preparation of Block Copolymer Terminated with an Antibody.**

The terminal -COOH group in PLGA is activated with N-hydroxysuccinimide ester using EDC and N-hydroxysuccinimide in CH<sub>2</sub>Cl<sub>2</sub>. After isolation of the activated material, antibody in water is 20 added to the solution of PLGA-hydroxysuccinimide ester in aqueous DMF, CH<sub>3</sub>OH, or DMSO solution. After 24 hours, the reaction mixture is applied onto HPLC (ion-exchange, gel-filtration, or reversed-phase) and the desired conjugate 25 fractioned.

**Example 4: Preparation of Nanospheres of PLGA-PEG**  
30 Sterically stabilized particles were prepared from diblock PLGA-PEG copolymers or from blends of PLGA and PLGA-PEG. These polymers were dissolved in a common solvent (ethyl acetate or methylene chloride). An oil-in-water emulsion was formed by vortexing and sonicating the mixture for 30 seconds. The organic solvent was then slowly 35 evaporated, at room temperature, by gentle stirring for two hours. Slow removal of the solvent allowed reorganization of the polymer chains inside and on the surface of the droplets, wherein the more

hydrophilic PEG chains migrated to the water interface, and the more hydrophobic PLGA chains remained inside the droplets to form the core of the nanospheres.

5 After removal of the organic solvent, the nanospheres were isolated from the aqueous phase by centrifugation. The nanospheres could later be readily redispersed in water.

10 To verify that PEG was present on the surface of the nanospheres, the surface composition of lyophilized particles was determined by X-ray photoelectron spectroscopy (XPS). Figure 4 is an X-ray photoelectron spectrum of the surface composition of lyophilized particles of PLGA-PEG 15 using MgK- $\alpha$  X-rays with a power of 300W. Carbon 1s envelopes were observed on analysis of the nanosphere powder. One predominant carbon environment is observed for PEG, corresponding to the ether carbon C-O. The spectrum of the PLGA 20 polymer exhibits three predominant carbon environments. All of these peaks are evident in the XPS spectrum of PEG-PLGA nanospheres, however, the PEG peak is predominant. Since the information obtained from XPS corresponds to the surface 25 layers of the nanosphere (about 5 nm deep), the spectrum indicates that PEG is concentrated on the surface of the nanosphere powder.

Moreover, it was confirmed that PEG remains on the surface of the nanoparticle after incubation 30 in distilled water for 24 hours. The nanospheres were recovered by centrifugation and freeze-drying. The XPS analysis shows that over time, the PEG peak diminished relative to the peaks corresponding to the PLGA, meaning that PEG was partially, but not 35 entirely, removed.

Figure 5 is a graph of the fraction of poly(ethylene glycol) removed from the surface of

the nanospheres during incubation for 24 hours at 37°C in phosphate buffer. This *in vitro* data supports the observation from XPS that less than 4% of the total PEG content is removed from the 5 surface of the nanosphere under these conditions.

**Example 5: Preparation of PLA-PEG Nanospheres Containing an Active Component.**

10 A solution of 2 ml methylene chloride, 25 mg lidocaine and 25 mg diblock polymers of Example 2 was prepared. After removal of methylene chloride by stirring the solution, nanospheres were isolated by centrifugation, giving lidocaine-loaded particles of a diameter of 15 nm.

15

**Example 6: Drug Release Characteristics**

20 Lidocaine and prednisolone (Sigma), were selected for encapsulation because of their low water solubility (defined as less than 5 mg/mL of water), high solubility in organic solvents (defined as more than 20 mg/mL in organic solvents such as chlorinated hydrocarbons, tetrahydrofuran, dimethyl formamide or dioxane) and ease of detection by UV spectrophotometry.

25

Release tests were carried out with nanospheres loaded with lidocaine in different amounts (20% wt, 33% wt), in phosphate buffer solution (PBS, pH 7.4) at 37°C. A dialysis membrane (50,000 cut-off) was filled with a 30 suspension of lyophilized nanospheres (10 mg/5 ml PBS) and then placed into 25 ml of PBS. Samples were taken from the outer solution, then replaced every time with fresh ones. Drug released was detected spectrophotometrically at 240 nm.

35

*In vitro* studies were performed to investigate the release characteristics of PEG-coated nanospheres, in particular to study the effect of the presence of PEG on the nanosphere

surface and the effect of the nanosphere core composition (polymer and drug nature, drug loading) on the drug release kinetics. Suspensions of nanospheres were easily obtained by redispersing

5 freeze-dried particles in aqueous solutions by vortexing, without any further additives.

Lidocaine was used as a model drug. The release of lidocaine was studied in particles made from linear PEG-PGLA copolymers.

10 These particles show a continuous release *in vitro* over several hours. The molecular weight does not effect the release pattern of PEG-PLGA nanospheres, since the drug is completely released in about ten hours using copolymers with a PEG m.w. of 5, 12, 20 KDa. The presence of PEG on the 15 surface of the nanospheres is not expected to modify the drug release. In ten hours, more than 90% of lidocaine was released from PLA nanospheres.

Drug release from nanospheres made from 20 PEG- $\epsilon$ -polycaprolactone is biphasic.

Because of polymer erosion, it would ordinarily be expected that a core made of polyanhydride should lead to a faster drug release. However, after an initial fast release in the first 25 two hours, drug release reached a plateau, although drug was released at a constant rate for an additional eight hours.

Polymer degradation kinetics were also investigated *in vitro*. With PEG-PLGA and PEG-PCL, 30 the polymers start to degrade after weeks.

Nanosphere cores made of polyanhydrides start to degrade immediately. In the first case, drug release is governed by a diffusion mechanism, since the drug can be completely released before polymer 35 degradation occurs. With polyanhydrides, polymer erosion affects drug release, and drug characteristics have a more important role in

release kinetics. The particle's small size and large surface area increases the rate of polymer erosion relative to other drug delivery systems, such as slabs, and afterwards drug solubility 5 governs the dissolution kinetics.

The amount of drug loading can have a strong effect on the release kinetics. PEG-PLGA nanospheres containing 33% wt of lidocaine can release the drug for over 12 hours. Surprisingly, 10 particles loaded with 10% of the drug can show complete drug release in 6 hours. Increased drug loading can cause part of the drug loaded in the core to recrystallize, as shown by DSC. The presence of crystals of a hydrophobic drug, such as 15 lidocaine, can slow down the release kinetics. ESCA studies performed on drug loaded nanospheres confirmed that drug crystals were not located on the nanosphere surface. The polymer composition was also modified and the drug loading was 20 increased up to 45% wt.

**Example 7: Evaluation of Biodistribution of <sup>111</sup>In-labeled Nanoparticles *in vivo*.**

25 Indium 111 was directly attached to the PLGA and PEG polymer chains by complex formation. In and diethyltriaminopentaacetic acid (DTPA) are reacted with stearylamine. The resulting compound, In-DTPA-stearylamine, is hydrophobic enough to 30 interact to the PLGA core. In this case, Mws of PLGA and PEG has little effect on the interaction. After incubation at 37°C in PBS or horse serum for more than 24 hours, there was no label loss, as 35 assessed by measuring the radioactivity of the supernatant solutions after centrifugation. This labelling method is therefore useful for *in vivo* studies, by gamma-scintigraphy or by direct

measurement of the radioactivity in the blood and/or different organs.

Preliminary biodistribution experiments were performed by injecting  $^{111}\text{In}$ -labeled uncoated 5 PLGA nanospheres and PEG-coated PLGA nanospheres into the tail vein of BALB/C mice (18-20 g). Five minutes after injection of uncoated PLGA nanospheres, 40% of nanosphere-associated  $^{111}\text{In}$  radioactivity was found in the liver and 10 approximately 15% in the blood. In the case of PEG-coated nanospheres, the results were reversed: 15% of injected radioactivity in the liver, 60% in the blood. After four hours, 30% of the nanospheres were still circulating in the blood, 15 whereas the non-coated ones had disappeared completely from the blood.

Figure 6 is a graph of the biodistribution of PLGA and PEG-PLGA in the liver and blood as a function of percent of injected dosage over time in 20 minutes (open square, PEG-PLGA with 12 kDa PEG in liver; closed diamond, uncoated PLGA in the liver; closed square, 12 k Da PEG-PLGA in blood; and open diamond, uncoated PLGA in the blood). As indicated, the PEG-coated PLGA nanospheres remained 25 in the blood for an extended period, while the uncoated PLGA nanospheres concentrated in the liver, where the are degraded and cleared.

Figure 7 is a graph of the clearance of uncoated PLGA and PEG-PLGA nanospheres in BALB-C 30 mice as a function of percent of injected dosage in tissue versus time in minutes (open square, PLGA; closed square, PLGA-PEG with 12 k Da PEG; closed triangle, PLGA-PEG with 5 k Da PEG; and open circle, PLGA-PEG, with 20 k Da PEG). As indicated, 35 the uncoated nanospheres were quickly cleared, and in general, the higher the molecular weight of the PEG, the longer the circulation time.

Figure 8 is a graph of the accumulation in the liver of uncoated PLGA and PEG-PLGA nanospheres in BALB-C mice as a function of percent of injected dosage in tissue versus time in minutes (open 5 square, PLGA; closed square, PEG-PLGA with 12 k Da PEG; closed triangle, PLGA-PEG with 5 kDa PEG; and open circle, PLGA-PEG with 20 kDa PEG). The uncoated PLGA nanospheres more quickly accumulated in the liver than the non-coated particles.

10 This invention has been described with reference to its preferred embodiments. Variations and modifications of the invention will be obvious to those skilled in the art from the foregoing 15 detailed description of the invention. It is intended that all of these variations and modifications be included within the scope of the appended claims.

We claim:

1. A particle with a core and a surface comprising a block copolymer of poly(alkylene glycol) and a biodegradable polymer selected from the group consisting of polyanhydride, polyorthoesters, polyhydroxyacids other than the homopolymer of lactic acid, polysiloxanes, polycaprolactone, and copolymers prepared from the monomers of these polymers, wherein the biodegradable moieties of the copolymer are in the core of the resulting particle, and the poly(alkylene glycol) moieties are on the surface of the resulting particle.

2. The particle of claim 1 further comprising a therapeutically effective amount of a substance to be delivered to those in need thereof.

3. The particle of claim 2 wherein the substance to be delivered is a biologically active substance selected from the group consisting of synthetic inorganic or organic molecules that cause a biological effect when administered *in vivo* to an animal, peptides, proteins, carbohydrates, nucleic acids, lipids, polysaccharides, and combinations thereof.

4. The particle of claim 1 further comprising molecules covalently bound to the surface of the particle via the terminal hydroxyl group of the poly(alkylene glycol), wherein the molecules are selected from the group consisting of molecules which have biological activity, molecules which can be detected, targeting molecules, and molecules affecting the charge, lipophilicity or hydrophilicity of the particle.

5. The particle of claim 4, wherein the targeting molecule is selected from the group consisting of compounds specifically reactive with a cell surface component.

6. The particle of claim 5 wherein the molecule is selected from the group consisting of antibodies and antibody fragments.

7. The particle of claim 5, wherein the poly(alkylene glycol) is covalently bound to the targeting molecules.

8. The particle of claim 1 wherein the diameter is less than one micron.

9. The particle of claim 1 wherein the diameter between one and 1000 microns.

10. The particle of claim 2 wherein the substance is a substance detectable by x-ray, fluorescence, ultrasound, CAT, PET, magnetic resonance imaging or radioactivity.

11. The particle of claim 1, wherein the poly(alkylene glycol) is poly(ethylene glycol).

12. The particle of claim 1 wherein the copolymer is a diblock or multiblock copolymer comprising two or more poly(alkylene glycol) blocks and a block of a polymer selected from the group consisting of poly(lactic-co-glycolic acid), poly(lactic acid), and poly(glycolic acid).

13. The particle of claim 1 wherein the block copolymer is a copolymer of poly(alkylene glycol) and a polymer selected from the group consisting of poly(lactic-co-glycolic acid), poly(lactic acid), and poly(glycolic acid), wherein the copolymer is blended with poly(lactic-co-glycolic acid) prior to forming the particle.

14. The particle of claim 1 wherein the surface of the particle is modified by attaching biodegradable polymers of the same structure as those forming the core of the particles by covalently linking the biodegradable polymers to the poly(alkylene glycol) moieties on the surface of the particle.

15. A method for making a particle with a core and a surface comprising:

(i) preparing a solution of a block copolymer of poly(alkylene glycol) and a biodegradable polymer selected from the group consisting of polyanhydride, polyhydroxyacids other than the homopolymer of lactic acid, polyorthoesters, polysiloxanes, polycaprolactone and copolymers prepared from the monomers of these polymers; and

(ii) precipitating the polymer from a solvent system such that the biodegradable moieties of the copolymer are in the core of the resulting particle, and the poly(alkylene glycol) moieties are on the surface of the resulting particle.

16. The method of claim 15 further comprising incorporating into or onto the particles a biologically active or detectable substance.

17. The method of claim 16 wherein the substance is a biologically active substance selected from the group consisting of synthetic inorganic or organic molecules that cause a biological effect when administered *in vivo* to an animal, peptides, proteins, carbohydrates, nucleic acids, lipids, polysaccharides, and combinations thereof.

18. The method of claim 16 wherein the substance is a substance detectable by x-ray, fluorescence, ultrasound, CAT, PET, magnetic resonance imaging or radioactivity.

19. The method of claim 16 wherein the copolymer is a diblock or multiblock copolymer comprising two or more blocks of poly(alkylene glycol) and one block of a polymer selected from the group consisting of poly(lactic-co-glycolic acid), poly(lactic acid), and poly(glycolic acid).

20. The method of claim 16 wherein the block copolymer is a copolymer of poly(alkylene glycol) and a polymer selected from the group consisting of poly(lactic-co-glycolic acid), poly(lactic acid), and poly(glycolic acid), wherein the copolymer is blended with poly(lactic-co-glycolic acid) prior to forming the particles.

21. The method of claim 16 wherein the surface of the particle is modified by attaching biodegradable polymers of the same structure as those forming the core of the particles by covalently linking the biodegradable polymers to the poly(alkylene glycol) moieties on the surface of the particle.

22. A method for delivering a substance to a patient comprising administering to the patient a composition comprising particles comprising a therapeutic amount of a substance to be delivered to a patient in need thereof and a copolymer of poly(alkylene glycol) and a polymer selected from the group consisting of polyanhydride, polyorthoesters, polyhydroxyacids other than the homopolymer of lactic acid, polysiloxanes, polycaprolactone and copolymers prepared from the monomers of these polymers, wherein the biodegradable moieties of the copolymer are in the core of the resulting particle and the poly(alkylene glycol) moieties are on the surface of the resulting particle.

23. A method for delivering a substance to a patient comprising administering to the patient a particle of claim 22 wherein the substance is a biologically active substance selected from the group consisting of synthetic inorganic or organic molecules that cause a biological effect when administered *in vivo* to an animal, peptides, proteins, carbohydrates, nucleic acids, lipids,

polysaccharides; and combinations thereof, which is present in a therapeutically effective amount in the particles.

24. A method for delivering a substance to a patient comprising administering to the patient a particle of claim 22 wherein the substance to be delivered is a substance detectable by x-ray, ultrasound, CAT, PET, fluorescence, magnetic resonance imaging and radioactivity, which is present in a detectable amount in the particles.

1/4




FIG. 1




FIG. 2

2/4




FIG. 3




FIG. 4

3/4




FIG. 5




FIG. 6

4/4




FIG. 7




FIG. 8

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB 94/08416A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C08J3/14 C08G63/664 C08G81/00 A61K9/51 A61K9/16

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C08J A61K C08G

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	EP,A,0 552 802 (EASTMAN KODAK COMPANY) 28 July 1993  see claims 1,3,4,9,10 see page 2, line 41 - line 58 see page 3, line 12 - line 29 see page 4, line 12 - line 35 ---	1-3,8, 10,11, 15-18, 22-24
X	EP,A,0 295 055 (YISSUM R&D COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM) 14 December 1988 see claims 1-3,21 see page 4, line 35 - line 36 ---	1-3,11 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

1 Date of the actual completion of the international search

Date of mailing of the international search report

23 November 1994

15. 12. 94

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Niaounakis, M

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US/08416

## C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP,A,0 092 918 (IMPERIAL CHEMICAL INDUSTRIES PLC) 2 November 1983 see claims 1,4-8 see examples 1,4 ---	1-3, 8-13, 15-20
Y	EP,A,0 520 888 (RHONE-POULENC RORER SA) 30 December 1992 cited in the application see claims 1-3,5,7 ---	1-3, 8-13, 15-20
A	EP,A,0 166 596 (IMPERIAL CHEMICAL INDUSTRIES PLC.) 2 January 1986 see page 10, line 31 - page 11, line 6 see claims 1,5,6 see examples 1,3 ---	1
P,A	WO,A,94 02122 (UNIVERSITY OF NOTTINGHAM) 3 February 1994 see claims 3,11 see page 6, line 12 - page 7, line 2 -----	1

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/EP/94/08416

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0552802	28-07-93	CA-A- JP-A-	2087125 5295120	24-07-93 09-11-93
EP-A-0295055	14-12-88	CA-A- JP-A- US-A-	1329854 1195862 4826945	24-05-94 07-08-89 02-05-89
EP-A-0092918	02-11-83	AU-B- AU-A- CA-A- DE-A- JP-A- JP-B- JP-A- US-A- US-A-	566010 1328083 1246265 3378250 4210928 5017245 58191714 4526938 4942035	08-10-87 27-10-83 06-12-88 24-11-88 03-08-92 08-03-93 09-11-83 02-07-85 17-07-90
EP-A-0520888	30-12-92	FR-A- CA-A- EP-A- WO-A- JP-T- NO-A-	2678168 2102186 0591374 9300101 6508831 934358	31-12-92 29-12-92 13-04-94 07-01-93 06-10-94 01-12-93
EP-A-0166596	02-01-86	AU-B- AU-A- CA-A- JP-A- US-A- US-A-	587977 4315085 1247271 61015846 4877606 4745160	07-09-89 02-01-86 20-12-88 23-01-86 31-10-89 17-05-88
WO-A-9402122	03-02-94	AU-B-	4717593	14-02-94

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**